This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names [Yahoo! Finance]
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]